Search Clinical Trials in the European Union

Duration
6-10 visits
Phase
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
401-420 of 604 trials

Severe Autoimmune Encephalitis: Bortezomib Study

We are investigating whether bortezomib is effective and safe for patients with severe autoimmune encephalitis. This trial focuses on individuals with specific autoantibodies related to their condition.

Autoimmune Encephalitis3-6 monthsEfficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementNeurologyRheumatology

Focal Onset Seizures: Extended-Release Levetiracetam Study

We are testing a new once-daily version of levetiracetam for people with drug-resistant focal onset seizures. The study aims to see if it reduces seizure frequency better than current treatments and a placebo.

Refractory Epilepsy3-6 monthsConfirmation phase (III)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Psoriatic Arthritis and Axial Spondyloarthritis: Sonelokimab Study

We are exploring how sonelokimab affects disease activity in patients with active psoriatic arthritis or axial spondyloarthritis. This study will help us understand its potential benefits and safety.

Axial SpondyloarthritisPsoriatic Arthritis3-6 monthsEfficacy phase (II)6-10 visitsNo PlaceboInvestigational MedicinesInternal MedicineRheumatology

Focal Seizures: PRAX-628 Study

We are testing a new medication, PRAX-628, for adults with focal seizures to see if it can reduce seizure frequency compared to a placebo. The study also looks at the safety and tolerability of this treatment.

Focal EpilepsyEfficacy phase (II)Confirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesPartially RemoteNeurology

Progressive Multiple Sclerosis: IMU-838 Study

We are testing a new medication, IMU-838, to see if it helps reduce brain atrophy in patients with progressive multiple sclerosis. This study compares its effects to a placebo to evaluate its safety and tolerability.

Progressive Multiple Sclerosis>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteNeurology

Arrhythmogenic Cardiomyopathy: Atorvastatin Study

We are evaluating whether atorvastatin can help slow down heart function decline in people with Arrhythmogenic Cardiomyopathy. The study also looks at its safety and effects on heart-related markers.

Arrhythmogenic Cardiomyopathy1-2 yearsEfficacy phase (II)6-10 visitsStandard MedicinesPartially RemoteCardiologyInternal Medicine

Painful Diabetic Peripheral Neuropathy: VX-993 Study

We are evaluating a new oral medication, VX-993, for people with pain from diabetic peripheral neuropathy. The study aims to determine if it effectively reduces pain and is safe to use.

Diabetic Peripheral Neuropathic Pain3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementDiabetologyNeurology

Antibiotic Treatment for Critically Ill Patients

We are studying whether a short course of high-dose antibiotics is as effective as standard treatment for critically ill patients with pneumonia, intra-abdominal infections, or bloodstream infections. This research may help reduce antibiotic use while maintaining patient safety.

Pneumonia and Bacterial Infections>2 yearsConfirmation phase (III)6-10 visitsNo PlaceboStandard MedicinesPartially RemoteInfectious DiseasesInternal Medicine

Juvenile Idiopathic Arthritis: Early Drug Withdrawal Study

We are exploring whether stopping medication early is safe and effective for children with juvenile idiopathic arthritis in remission. This study also aims to identify new biomarkers that may help predict flare-ups after treatment withdrawal.

Juvenile Idiopathic Arthritis3-6 monthsMonitoring phase (IV)6-10 visitsNo PlaceboStandard MedicinesPediatricsRheumatology

Lichen Simplex Chronicus: Dupilumab Injections

We are studying whether dupilumab injections can help reduce itching in adults with Lichen Simplex Chronicus who haven't found relief from other treatments. The trial will also look at how this treatment affects sleep and overall quality of life.

Neurodermatitis6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementAllergologyDermatology

Chronic Low Back Pain: Melatonin Study

We are investigating whether melatonin can help reduce pain in patients with chronic low back pain. Participants will compare its effects to a placebo over six weeks.

Chronic Low Back Pain6-12 monthsConfirmation phase (III)6-10 visitsStandard MedicinesCost ReimbursementInternal MedicineOrthopedics and Traumatology

CRN04894 for Hormonal Imbalance

We are studying the safety and effectiveness of CRN04894 in participants with hormonal imbalances. The goal is to see how it affects hormone levels and overall health.

Congenital Adrenal HyperplasiaEfficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesPartially RemoteEndocrinologyPediatrics

Sepsis-Induced Hypotension: REGN7544 Treatment Study

We are studying REGN7544 to see if it can help adults with sepsis-induced hypotension manage their blood pressure and reduce the need for other medications. The trial will also assess the safety and effects of this treatment.

Sepsis-Induced Hypotension3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementPartially RemoteCardiologyInfectious Diseases

Thyroid Eye Disease: VRDN-003 Treatment Study

We are investigating whether VRDN-003 can improve symptoms in individuals with active thyroid eye disease. The study will also check if the treatment is safe and well-tolerated compared to a placebo.

Thyroid Eye Disease1-2 yearsConfirmation phase (III)6-10 visitsPost-Trial Drug AccessInvestigational MedicinesCost ReimbursementPartially RemoteEndocrinologyOphthalmology

Rheumatoid Arthritis: AP1189 with Methotrexate

We are studying a new oral medication, AP1189, for people with early rheumatoid arthritis who haven't received other treatments. The goal is to see if it works better with methotrexate than methotrexate alone.

Rheumatoid Arthritis3-6 monthsEfficacy phase (II)6-10 visitsInvestigational MedicinesCost ReimbursementRheumatology

Multiple Myeloma: Isatuximab with Novel Agents

We are studying a new combination treatment for people with relapsed or refractory multiple myeloma. This trial aims to find effective doses and evaluate how well these combinations work compared to standard treatments.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboStandard MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Belumosudil and Dexamethasone

We are studying a new combination of treatments for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if this combination improves treatment outcomes.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Multiple Myeloma: Isatuximab with Evorpacept and Dexamethasone

We are studying a new treatment combination for people with relapsed or refractory multiple myeloma. The goal is to find the best dose and see if it improves treatment responses compared to existing options.

Plasma Cell Myeloma Refractory>2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsPost-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Nephrogenic Diabetes Insipidus: Amiloride Treatment Study

We are investigating whether amiloride can help patients with nephrogenic diabetes insipidus caused by lithium treatment for bipolar disorder. The study looks at its effects on urine concentration, thirst, and quality of life.

Bipolar Disorder with Lithium Treatment>2 yearsEfficacy phase (II)6-10 visitsPost-Trial Drug AccessStandard MedicinesCost ReimbursementPartially RemoteNephrologyPsychiatry

Hodgkin's Lymphoma: Nivolumab and Chemotherapy Study

We are studying a new treatment approach using nivolumab followed by chemotherapy for patients with Hodgkin's lymphoma that hasn't responded to previous therapy. The goal is to see if this combination improves treatment outcomes and safety.

Refractory Hodgkin LymphomaEfficacy phase (II)6-10 visitsNo PlaceboStandard MedicinesHematologyOncology